Anzeige
Meldung des Tages: Warum diese Aktie einer der großen Gewinner im neuen Goldzyklus sein könnte

Intensity Therapeutics Aktie News

Aktie
WKN:  A3C9BX ISIN:  US45828J1034 US-Symbol:  INTS Branche:  Biotechnologie Land:  USA
0,3487 $
-0,0141 $
-3,89%
0,29532 € 04.02.26
Depot/Watchlist
Marktkapitalisierung *
15,70 Mio. €
Streubesitz
82,60%
KGV
-1,09
Index-Zuordnung
-

Intensity Therapeutics News

13.01.26 - PR Newswire
Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities
Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities PR Newswire
11.12.25 - PR Newswire
Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium PR Newswire
05.12.25 - PR Newswire
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement PR Newswire
04.12.25 - PR Newswire
Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium PR Newswire
06.11.25 - PR Newswire
Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
31.10.25 - PR Newswire
Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock
Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock PR Newswire
30.10.25 - PR Newswire
Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal
Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science ...
10.09.25 - PR Newswire
Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update
Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-​Negative Breast Cancer Study Update PR Newswire
02.09.25 - PR Newswire
Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference PR Newswire
07.08.25 - PR Newswire
Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
04.08.25 - PR Newswire
Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025
Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025 PR Newswire
30.06.25 - PR Newswire
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch PR Newswire
30.06.25 - PR Newswire
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch PR Newswire
30.06.25 - PR Newswire
Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)
Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST) PR ...
20.06.25 - PR Newswire
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology PR Newswire
20.06.25 - PR Newswire
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology PR Newswire
11.06.25 - PR Newswire
Intensity Therapeutics, Inc. Announces Pricing of Public Offering
Intensity Therapeutics, Inc. Announces Pricing of Public Offering PR Newswire
11.06.25 - PR Newswire
Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock PR Newswire
11.06.25 - PR Newswire
Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study
Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-​of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized ...
29.05.25 - PR Newswire
Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting PR Newswire

Newssuche

Videos

newspaper
03.02.26
2026 02 03 17 34 Trendjumper Einführung
Zunächst inormieren wir unsere Stammkunden bezüglich des bevorstehenden Seminars und bieten für ... Mehr »